Merck and Orna Therapeutics have announced a collaboration agreement to discover, develop and commercialize Orna’s next generation oRNA technology across multiple programs, including vaccines and therapeutics in infectious disease and oncology.
Vaccibody, a Norway-based pioneer in the neoantigen cancer vaccine space, has changed its name to Nykode Therapeutics, and has entered into a license and collaboration agreement with US company, Regeneron, to develop vaccines against cancer and infectious...
CSSi LifeSciences and BioMARC have announced a strategic partnership to provide 'fully cohesive product development and support' for vaccine and biologic development.
PPD has expanded its central lab testing services at its Brussels and Singapore labs and will offer additional services in microbiology, peripheral blood mononuclear cell and molecular pathology services.